Acumen Pharmaceuticals (ABOS) investor relations material

Executive summary

• Focused on advancing sabirnetug, an anti-Aβ oligomer IgG2 monoclonal, through the phase II ALTITUDE-AD trial, with top-line efficacy results expected late 2026.

• Two Enhanced Brain Delivery (EBD) candidates, ACU301 and ACU401, were nominated in June 2026, with IND filing for the lead candidate targeted for mid-2027.

• Entered a collaboration with JCR Pharmaceuticals for EBD therapies, including a $9.25 million option exercise payment in July 2026.

• Investor relations day scheduled for September 16th to review the investment thesis ahead of phase II data.

Financial highlights

• Ended Q2 2026 with $110.2 million in cash and marketable securities, expected to fund operations into early 2027.

• R&D expenses were $27.8 million for Q2 2026, down from $37.1 million in Q2 2025, mainly due to lower manufacturing and CRO costs.

• G&A expenses were $4.7 million for Q2 2026, nearly flat year-over-year.

• Net loss for Q2 2026 was $32.7 million, compared to $41.0 million in Q2 2025.

• Net loss for the six months ended June 30, 2026 was $53.5 million, down from $69.7 million year-over-year.

Outlook and guidance

• Top-line ALTITUDE-AD phase II results anticipated late 2026, including primary and key secondary endpoints, safety, and biomarker data.

• IND filing for lead EBD candidate expected mid-2027.

• Cash runway projected to support operations into early 2027, but substantial doubt exists about the ability to continue as a going concern without additional funding.

• Expenses and operating losses are expected to increase as clinical and preclinical programs advance.